NASDAQ:CRVS

Corvus Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy CRVS

*Your capital is at risk

$11.60

-0.0900 (-0.770%)

At Close: Jun 03, 2026

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

09:15am, Thursday, 02'nd Nov 2023

BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new interim data fr

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2023 Earnings Call Transcript

09:57pm, Tuesday, 08'th Aug 2023

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2023 Earnings Call Transcript August 8, 2023 4:30 PM ET Company Participants Zack Kubow - IR-Real Chemistry Leiv Lea - CFO Richard Miller - CEO Conferenc

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

08:30am, Tuesday, 01'st Aug 2023

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

3 Hot Penny Stocks To Watch Before Next Week

02:19pm, Wednesday, 07'th Jun 2023

Penny stocks typically trade for less than $5 and generally belong to small companies often overlooked by mainstream investors. Yet, for those willing to navigate the inherent risks, these cheap stock

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

08:30am, Wednesday, 31'st May 2023

BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president a

3 High-Potential Penny Stocks to Buy Now

08:11am, Wednesday, 31'st May 2023

When it comes to penny stocks to buy now, be aware of the risks. While some of these little guys can rocket, some will be duds, which can wipe out your account.

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

09:00am, Wednesday, 17'th May 2023

BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818,

Corvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Market

04:25pm, Friday, 12'th May 2023

Additional Phase 1b data for CPI-818 in T cell lymphoma is expected in this quarter. Phase 2 data for Ciforadenant is expected this year.

The 3 Best Biotech Stocks Under $1 to Buy for April

08:21pm, Tuesday, 04'th Apr 2023

Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript

10:55pm, Tuesday, 28'th Mar 2023

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Of

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

04:05pm, Tuesday, 21'st Mar 2023

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

04:35pm, Tuesday, 14'th Mar 2023

Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad potenti

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by